TRIM33 and cancer: Classically, TIF1γ, NXP2 and SAE1 antibodies delimit a subset of subjects under a high risk of cancer, indicating the need for neoplastic screening and close monitoring, especially in the first 3 years after the onset of symptoms (27, 31–41).